Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

A cancer diagnosis does not end when treatment does. For a significant portion of patients, the psychological distress it triggers can persist well into survivorship, often going unrecognized and untreated and occurring at any point following a diagnosis.¹ Research shows the prevalence can range between 3% and 33%.^2-6

Unlike general cancer-related stress, which is common and typically resolves over time, trauma and posttraumatic stress are more intense, can last longer, and meaningfully disrupt a patient’s daily functioning, from missing follow-up appointments to withdrawing from essential support relationships. Symptoms that overlap with the physical effects of treatment—fatigue, sleep disruption, difficulty concentrating—are often at the root of why trauma and posttraumatic stress go unrecognized. There is also a cultural tendency to normalize emotional distress as an expected part of the cancer experience, according to experts interviewed by The American Journal of Managed Care^® (AJMC^®). Further, despite their prevalence, trauma-informed screening remains inconsistent across oncology practices, leaving many patients without timely intervention.

When Stress Becomes Something More

Treatment for cancer is medically necessary, but it can also be emotionally debilitating. Cancer forces many patients to confront their own mortality, often for the first time, explained Jane Meisel, MD, FASCO, professor, departments of hematology and medical oncology and gynecology and obstetrics, and codirector of breast medical oncology, Emory University School of Medicine and Winship Cancer Institute.

For many, this existential shift does not resolve when treatment ends or when surgery is complete. In a significant portion of survivors, it takes on the clinical weight of posttraumatic stress disorder (PTSD).^2,3,6

“Cancer-related posttraumatic stress is a very common and shared experience by many cancer patients,” said Bridget Vazquez, PsyD, a clinical health psychologist in the Department of Supportive Care Medicine at City of Hope in Duarte, California. But she draws an important distinction between a manageable stress response and a clinical PTSD diagnosis, one that providers and patients alike frequently miss. “It’s not just distress,” she explained. “It’s a distress that disrupts how someone lives their life.”

Unlike a single traumatic event, cancer is an ongoing process. Patients navigate repeated medical stressors—invasive procedures, harsh treatment-related adverse effects, potential disfigurement, prolonged hospitalizations—each one layering onto the last.⁷ The symptoms of PTSD in this population fall into recognizable clusters: re-experiencing or reliving trauma through intrusive memories or nightmares; avoidance behaviors such as skipping follow-up appointments or withdrawing from loved ones; changes in mood and cognition, including self-blame and persistent fear of recurrence; and physical hyperarousal.

“I’ve had patients who come and tell me, ‘I didn’t go to this appointment because I was afraid that they were going to tell me that the cancer came back,’” Vazquez said. However, she also cautions against conflating avoidance with noncompliance, because what may appear to be a patient refusing to engage with care may actually be a trauma response in the form of a protective mechanism that, left unaddressed, can lead to real delays in treatment and increased health risk. “I encourage our providers, and even myself, to reframe it by shifting from asking what’s wrong with the patient to what has the patient been through…just making that small change in perspective can really help,” she emphasized.

Risk Builds Across the Entire Journey

During active treatment, many patients enter what Vazquez called “go mode,” focusing on each step of care while juggling appointments, medications, and daily responsibilities. When treatment ends, that structure disappears, leaving more room to process what they have endured. Fear of recurrence, ongoing monitoring, and the loss of the care team’s sense of security can make survivors feel that the experience is still not over.

Therefore, determining when in the cancer trajectory a patient is most vulnerable to PTSD is not straightforward, Vazquez explained. Posttraumatic stress symptoms—anxiety, intrusive thoughts, trouble sleeping—can surface early, “especially around diagnosis and during treatment,” when everything can feel sudden and overwhelming. But full PTSD, she noted, may carry a higher risk during survivorship. “Not everyone with these symptoms will go on to develop PTSD.”

For caregivers, that suspended state is just as acute. Skylar Jeremias, associate editorial director for Center for Biosimilars^® and AJMC, has spent much of the past year as a primary caregiver for her mother, who received 2 separate cancer diagnoses within months of each other—an aggressive uterine cancer followed by a rare thyroid cancer. The uncertainty, she said, restructures how you think about the future entirely. It is a holding pattern that, for many caregivers and patients alike, has no clear end date.

“My life plans for up until the next scan,” Jeremias said, “and if all goes well, then we can relax and do fun things.”

Vazquez added that certain groups face an elevated risk, and they include patients with more advanced disease or intensive treatment regimens; those with a prior history of trauma or existing mental health conditions, particularly anxiety and depression; younger patients; and individuals from underserved or minority populations, who may face additional stressors or barriers to care.

In breast cancer specifically, the impacts of the diagnosis and treatment on body image, sexuality, and fertility losses intersect uniquely, Meisel explained. For example, losing a breast, entering early menopause, or losing the ability to breastfeed can be psychologically defining—particularly for younger women, who are disproportionately likely to present with the most aggressive cancers requiring the most intensive treatment. Further, each phase of treatment can carry its own toll.

“I think with breast cancer we often ask patients in the curative setting to gear up for what amounts to be a little bit of a marathon,” Meisel said.

Why PTSD Gets Missed

Several structural and cultural forces converge to obscure PTSD in cancer patients. Most notably, the physiological symptoms of trauma overlap substantially with the adverse effects of cancer treatment. Patients who embrace a “fighter” or “warrior” mindset may view acknowledging distress as incompatible with strength, Vazquez noted. In some communities, there may also be discomfort or unfamiliarity with mental health frameworks, making it harder for providers to identify what a patient is experiencing, Meisel and Vazquez separately explained to AJMC.

That instinct to project strength can delay emotional reckoning in ways that compound over time, and caregivers are not immune to it. “At first you convince yourself that if you can adapt quickly and aren’t emotionally falling apart, then everything will be okay,” Jeremias explained. “But that isn’t promised, and you end up being forced to confront the harder emotions eventually regardless of whether the person survives or is cancer-free.”

Although many oncology clinics screen for general distress, that screening does not consistently include specific tools for identifying PTSD. Time constraints during visits and limited provider training in trauma-informed care further reduce the chances of early identification, so that the true mental health impact is too often missed.⁸ Meisel has seen this play out in her breast cancer practice.

“There is a lot of literature suggesting that PTSD after breast cancer is pretty common. I definitely see that come up in my clinic in a myriad of ways,” she said. “It can even be as significant as patients coming in for follow-up who have high blood pressure and elevated heart rate in the exam room when they present for follow-up, simply because their memories of this place where they got chemotherapy or where they got bad news are pretty strong—and this is the body’s natural response to significant stress.”

The Role of Social Support and Its Limits

Lingering fatigue, ongoing therapy-related adverse effects, and the emotional residue of the experience remain largely invisible to those outside the cancer world, leaving survivors to navigate a gap between what others expect them to feel and what they actually do feel. The transition out of active treatment can paradoxically deepen distress, Vazquez and Meisel concurred. Although survivorship is typically framed by society as a cause for celebration, many patients find the end of treatment destabilizing rather than liberating. Fear of recurrence fills the space left by frequent clinical contact.

“Often, people don’t feel normal. They feel forever changed, whether it’s chemo fatigue that can linger for a long time, whether it’s side effects from pills,” Meisel noted. “While friends and family see that you’re done with chemo and surgery and radiation, and want to celebrate that, they may not understand that 5 to 10 years of endocrine therapy can still be a challenge—and that there is the lingering fear of recurrence that never completely goes away.”

For patients, that visibility gap is not only emotional but also physical. “When you go through a treatment that makes you lose your hair, it can be pretty obvious. Your cancer is still on full display even though you’re done your treatments or most of the cancer was removed during surgery,” Jeremias observed. “You still look visibly sick, and depending on what treatment you received, you probably still feel sick, too. Cancer follows you even after it’s gone because it does so much to your body and your view of yourself in your own body.”

A patient’s support network is one of the most powerful protective factors against cancer-related PTSD. When patients feel genuinely supported, they are less likely to feel isolated and better able to process and cope with ongoing stress. At the same time, Vazquez said, “not all support is equally helpful. Interactions that feel dismissive, critical, overwhelming, or intrusive can actually increase distress. Trauma symptoms themselves, like withdrawal or emotional numbing, can make it harder for patients to stay connected.”

Clinically, this means actively involving identified caregivers in treatment discussions and connecting patients and families with counseling or support groups to help build and sustain a more supportive environment, Meisel and Vazquez explained.

A System That Must Catch Up

Although interviewed separately, Vazquez and Meisel converged on a clear set of solutions. Both agreed that early referral is essential.

Meisel raises mental health support at the very first patient visit, placing it alongside nutrition counseling and social work resources to normalize it before a crisis develops. “I feel like it’s never too early to do that,” she said. “I often tell patients that even if you’ve never struggled with mental health before, this kind of diagnosis and the treatment can be very challenging.” For patients already experiencing persistent symptoms, Vazquez recommends disclosing what they are experiencing to their care team as an entry point to further evaluation, whether that leads to trauma-focused cognitive behavioral therapy (CBT), peer support groups, social work services, or chaplain care.

Meisel also highlighted 2 underutilized interventions. For patients on antiestrogen therapy cycling through poor sleep, hot flashes, and mood disruption, low-dose antidepressants such as escitalopram or venlafaxine can provide meaningful relief without interfering with endocrine therapy. Also, CBT for insomnia, which she actively refers patients to, addresses sleep disruption that, left untreated, compounds anxiety and mood symptoms throughout survivorship.

At the system level, Vazquez argues that education and training for oncology providers is the critical first step, and Meisel envisions a structural complement: implementing a rapid PTSD screen alongside existing distress screening tools, so that survivors who score above a threshold are automatically flagged for follow-up.

From the caregiver side, Jeremias offered a more granular ask: that oncology teams consider tailoring the emotional and informational support they offer to a patient’s or caregiver’s existing level of health literacy. “I feel like aftermath information needs to be tailored to the level of health literacy the person/caretaker already has,” she said.

For those with a strong clinical background, she noted, more information—including what comes next if a scan brings bad news—can actually reduce anxiety rather than add to it. For others, that same information could overwhelm them. The point, she suggested, is not a single protocol but attentiveness to who is in the room.

The throughline across both perspectives is that trauma and PTSD following a cancer diagnosis are not rare exceptions. They are clinically significant, underrecognized consequences of a disease that already commands extraordinary medical resources. Extending that same rigor to the psychological aftermath, from diagnosis through survivorship, is not supplemental care. It is a continuation of it.

References
1. Healing & recovery. Liv & Let. Accessed June 1, 2026. https://www.livandlet.com/healing-recovery

2. Cancer-related post-traumatic stress (PDQ)–health professional version. National Cancer Institute. Updated February 25, 2025. Accessed June 1, 2026. https://www.cancer.gov/about-cancer/coping/survivorship/new-normal/ptsd-hp-pdq

3. High levels of traumatic stress found in caregivers of adult cancer patients. ecancer. March 20, 2025. Accessed June 1, 2026. https://ecancer.org/en/news/26178-high-levels-of-traumatic-stress-found-in-caregivers-of-adult-cancer-patients

4. Doolittle M. Post-traumatic stress disorder in people with cancer. Memorial Sloan Ketting Cancer Center. Accessed June 1, 2026. https://www.mskcc.org/videos/post-traumatic-stress-disorder-people

5. Chen L, Wang GZ, Chi YY, Zhao J. Risk factors for post-traumatic stress disorder among young and middle-aged cancer patients in the intensive care unit: a case-control study. World J Clin Cases. 2023;11(25):5870-5877. doi:10.12998/wjcc.v11.i25.5870

6. Guolo F, Del Sette P, Riccardi F, et al. Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications. Leuk Lymphoma. 2026;67(6):1283-1289. doi:10.1080/10428194.2026.2634180

7. American Psychiatric Association. Diagnostic and Statistical Manual of Disorders, Fifth Edition, Text Revision. American Psychiatric Association; 2025. Accessed June 1, 2026.

8. Moxam A. PTSD and cancer: understanding trauma during and after a cancer diagnosis. ETHOS treatment. March 26, 2026. Accessed June 1, 2026. https://www.ethostreatment.com/ptsd-and-cancer/